President Donald J. Trump has done it again — delivering real results for the American people. In a major win for seniors, working families, and patients across the country, President Trump announced new landmark deals with pharmaceutical giants Novo Nordisk and Eli Lilly to dramatically slash the cost of weight-loss and diabetes drugs that millions rely on.
🇺🇸 Trump’s America-First Health Plan Pays Off
Under President Trump’s direction, both drug companies agreed to historic price reductions that will finally make vital medications affordable for everyday Americans.
- Novo Nordisk confirmed that the lowest doses of its FDA-approved weight-loss drug Wegovy will soon cost just $149 per month — a fraction of today’s typical price tag.
- The company will also cut prices for Ozempic and other injectables across Medicare Part D, Medicaid, and self-pay options.
- Trump hailed the move as “a triumph for American patients that will save lives and improve the health of millions.”
These new discounts are part of the Trump Administration’s broader Most Favored Nation Initiative, designed to ensure Americans never pay more than patients overseas for the same medicine.
💊 Huge Savings for Families and Seniors
Eli Lilly followed suit with deep price cuts on its most popular obesity and diabetes treatments:
- Zepbound will now start at $299 for the lowest dose and $449 for higher doses — roughly $50 less than current prices.
- Orforglipron, the company’s groundbreaking oral weight-loss pill awaiting FDA approval, will launch at $149 for the lowest dose.
- Medicare recipients will pay a maximum of $50 each month for Zepbound and Orforglipron — offering significant savings for seniors on fixed incomes.
- Additional drugs, including Mounjaro, Trulicity, and Emgality, will also be discounted up to 60% through Lilly’s digital platform.
These price drops mark one of the largest health-care savings initiatives since Trump’s previous executive orders to lower insulin and EpiPen costs.
⚖️ Fighting for Fair Prices — and Winning
GLP-1 medications like Wegovy, Ozempic, and Zepbound help patients lose weight, regulate blood sugar, and improve overall health. But for years, Big Pharma and Washington insiders kept prices sky-high while foreign nations paid pennies on the dollar.
President Trump’s America-First leadership changed that. His direct negotiations forced drug companies to put Americans first, ending the global price gouging that punished U.S. consumers.
“For decades, Americans have been paying the highest drug prices in the world,” Trump said. “That ends under my administration. We’re putting our people first again.”
🏥 Trump’s Vision: Affordable Health Care for Every American
Both companies are now expanding direct-to-consumer platforms to help patients bypass red tape and middlemen:
- NovoCarePharmacy (by Novo Nordisk) allows patients without insurance to buy Wegovy and Ozempic directly at lower prices.
- LillyDirect (by Eli Lilly) lets consumers order Zepbound, Mounjaro, and more — with discounts up to 60% off retail.
These platforms are the direct result of Trump’s push to make health care transparent, competitive, and affordable again.
❤️ A President Who Keeps His Promises
President Trump’s new drug-pricing victories prove what millions of Americans already know — he fights for the people, not the politicians or lobbyists. While career bureaucrats talk, Trump delivers.
His leadership continues to put American families first, lower costs, and protect the middle class — keeping his promise to Make America Healthy Again.